Skip to content
Menu

Vor Biopharma Inc. VOR

Full chart Compare
Set alert

Price alert · VOR

All alert types
19.19 USD +0.67 (+3.62%)

Regular-session close

19.40 +0.21 +1.09%

After hours · Nov 20, 4:39 PM ET

17.99 Day range 19.91
6.86 52-week range 25.10
YTD
+46.71%
1 year
+179.74%

5D -0.45 (-2.29%)

181920MonTueWedThuFri19.19
Market cap
1.18B
EPS (ttm)
300.56
Shares out
61.43M
P/E ratio
0.06
Forward P/E
-5.74
YTD return
+46.71%
1-year return
+179.74%
50-day average
19.55
200-day average
17.64
Enterprise value
659.02M
Volume
1.56M
Avg volume
931.03K
Open
18.14
Previous close
18.52
Day's range
17.99 – 19.91
52-week range
6.86 – 25.10
Beta
1.83
Analysts
Strong Buy
Price target
39.00 (+103.2%)
Earnings date
Mar 29, 2027

Key statistics

Free cash flow
-46.94M
Total cash
481.55M
Total debt
2.81M
Short % of float
14.28%

Fundamental scorecard

6 of 25 checks passed on VOR’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
VOR Revenue — quarterly 0
VOR Net income — quarterly -86.73M
VOR EPS — quarterly -1.45

Earnings

VOR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 29, 2027Mar 30, 2027-0.92———
Oct 30, 2026Sep 30, 2026-1.08-1.45-0.37-34.26%
Aug 11, 2026Jun 30, 2026-0.69-1.16-0.47-68.12%
May 13, 2026Mar 31, 2026-0.75-0.73+0.02+2.67%
Mar 30, 2026Dec 31, 2025-1.1444.50+45.64+4,003.51%
Nov 13, 2025Sep 30, 2025-3.06-121.63-118.57-3,874.84%

Upgrades / downgrades

VOR analyst upgrades and downgrades
DateFirmActionFromTo
Oct 21, 2026William Blairinit—Outperform
Aug 12, 2026WedbushmainNeutralNeutral
May 18, 2026HC Wainwright & Co.reitBuyBuy
May 14, 2026WedbushmainNeutralNeutral
Apr 15, 2026HC Wainwright & Co.mainBuyBuy
Mar 31, 2026WedbushmainNeutralNeutral

About Vor Biopharma Inc.

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
vorbio.com

News

Your note

Sign in to keep a note on VOR — it syncs with the Stock Master app.

Insider holders

VOR insider holders
InsiderRelationLatest transactionDateShares held
ANG ROBERT M.D.Chief Executive OfficerStock Award(Grant)Feb 2, 2025921,739
ATTAR EYAL COfficerSaleFeb 12, 2025126,625
CHAKRABORTY TIRTHAOfficerStock Award(Grant)Feb 2, 2025221,272
CHOI HAN WOOKChief Financial OfficerStock Award(Grant)Feb 2, 202552,500
MAHATME SANDESHChief Financial OfficerStock Award(Grant)Jul 8, 202513,882,800
RA CAPITAL HEALTHCARE FUND,L.P.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityAug 23, 20260

Institution ownership

VOR institution ownership
Holder% heldSharesValueReported
FMR, LLC11.00%6,759,007129.71MSep 29, 2026
TCG Crossover Management, LLC9.23%5,673,078108.87MSep 29, 2026
RA Capital Management, L.P.7.33%4,503,88286.43MSep 29, 2026
FCPM III Services B.V.5.54%3,405,27965.35MSep 29, 2026
Blackrock Inc.5.38%3,306,49463.45MSep 29, 2026
Venrock Adviser, LLC4.95%3,041,71958.37MSep 29, 2026

Fund ownership

VOR fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.52%1,550,88529.76MJun 29, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio2.28%1,399,60526.86MSep 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Growth Fund2.07%1,270,14424.37MAug 30, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.78%1,091,62620.95MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF1.62%996,33419.12MSep 29, 2026
Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund1.23%758,11214.55MAug 30, 2026